Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?

Bristol-Myers Squibb’s Thursday announcement that it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the return has industry watchers wondering which company will be the next to follow suit.